TIPS (TIPPS)

A transjugular intrahepatic portosystemic shunt (TIPS) is a radiology procedure that lowers portal hypertension by creating a controlled channel between the portal vein and a hepatic vein inside the liver [1]. In practical terms, it reduces the pressure driving blood into fragile varices and pressure-driven fluid leaks that cause ascites [3].

TIPS can be life-saving for uncontrolled variceal bleeding and can be highly effective for selected patients with refractory ascites—but it also increases the risk of hepatic encephalopathy (HE) in a meaningful subset of patients [4].

TIPS is performed by an interventional radiologist through a vein in the neck (the jugular vein). A pathway is created through the liver tissue, connecting the portal circulation to the systemic venous circulation, and a stent is placed to keep that channel open [1].

The goal is straightforward: reduce portal pressure. When portal pressure falls, varices are less likely to rupture and (in selected patients) ascites formation can decrease over time [3].

The most widely accepted indications for TIPS in cirrhosis include:

• Acute variceal bleeding that is uncontrolled or at high risk for failure with standard therapy [1] [2].
• Secondary prophylaxis in selected patients who re-bleed despite optimized medicines/endoscopy [1].
• Refractory ascites in carefully selected patients (not everyone is a safe candidate) [3].

Modern consensus statements emphasize patient selection: the “right” TIPS in the “right” patient can be transformative, while a poorly selected TIPS can worsen encephalopathy or precipitate liver failure [2] [4].

Acute variceal hemorrhage is managed in phases: stabilization, early antibiotics and vasoactive therapy, urgent endoscopy (often EVL), and then prevention of early re-bleeding [5] [1].

Rescue TIPS is considered when bleeding cannot be controlled or rapidly recurs despite optimal medical and endoscopic therapy [1]. In carefully selected high-risk patients, early/pre-emptive TIPS (typically within days of the index bleed) has been associated with better bleeding control and outcomes versus continuing standard therapy alone [6] [2].

Translation for patients and caregivers: the team is trying to prevent the “second bleed,” because that is often where outcomes worsen. TIPS is one of the strongest tools to change the pressure driving the problem [1].

Ascites becomes “refractory” when it cannot be controlled with sodium restriction and diuretics (or when diuretics cause unacceptable kidney injury or side effects). In that setting, repeated large-volume paracentesis is common, and TIPS may be considered in selected patients [3].

The trade-off is real: while TIPS can reduce ascites burden and paracentesis frequency in some patients, it also increases the risk of HE, and not all patients have enough liver “reserve” to tolerate the hemodynamic changes [2] [4].

Ask your team to explain why you are (or are not) a good candidate: MELD trajectory, bilirubin, kidney function, heart function, and prior encephalopathy history usually matter more than any single symptom.

The most feared “everyday” complication after TIPS is hepatic encephalopathy. The reason is intuitive: TIPS diverts blood away from liver detoxification, so more gut-derived toxins can reach the brain [4].

Other meaningful risks include shunt dysfunction/stenosis (requiring surveillance and sometimes revision), cardiac overload in susceptible patients, and (in advanced disease) risk of worsening liver failure—another reason that selection is central [2].

Practical red flags to report promptly after TIPS include: new confusion, sleep–wake reversal, falls, tremor worsening, severe shortness of breath, chest pain, fever, or rapidly increasing abdominal distension.

Most centers follow patients after TIPS with a combination of symptom review, lab monitoring, and imaging surveillance of shunt patency (often Doppler ultrasound), particularly in the first months [2].

Many patients are also placed (or continued) on HE-prevention strategies if there is prior HE history or early symptoms—commonly lactulose-based plans and, when appropriate, rifaximin-based plans—tailored by your transplant/hepatology team.

The simplest “success metric” is not a number on a report. It is fewer bleeding events, fewer ICU admissions, fewer paracenteses (when ascites is the indication), and stable cognition and function.

TIPS is often used as a bridge—a way to keep a patient stable enough to reach transplant safely when portal hypertension complications are the dominant threat. A history of variceal bleeding itself is a major milestone that often accelerates transplant evaluation and planning [1] [3].

Key point: TIPS does not “cure” cirrhosis. It treats the pressure-driven complications. If the underlying liver function continues to decline, transplant planning remains central.

These videos are included to help patients and caregivers visualize the procedure and understand the general concept. They are not a substitute for your transplant center’s specific instructions.

• What is the main reason you are recommending TIPS for me—bleeding control, ascites control, or both? [1]
• Am I the kind of patient where “early/pre-emptive TIPS” is considered beneficial, or would you only use TIPS as rescue? [6]
• Based on my history, how high is my encephalopathy risk after TIPS, and what is our prevention plan? [4]
• What follow-up testing will you use to monitor shunt function (and how often in the first year)? [2]
• How does TIPS change (or not change) my transplant timing and listing strategy? [3]